SALT LAKE CITY, Dec. 21, 2016 /Weed Wire/ — ISA Scientific, a Delaware (USA) corporation, whose activities are centered on making non-psychoactive, safe and effective therapeutic products based on cannabis plant chemistry, has announced completion of its full rebrand and is now operating under a new name, ANANDA Scientific.
The re-branding to ANANDA Scientific was done to capitalize on the global cannabidiol (CBD) market, which is anticipated to reach $2.1 billion in consumer sales by 2020, according to the Hemp Business Journal.
“This rebrand was done to improve corporate positioning and brand development. It will help advance the company’s goals in an emerging and rapidly growing marketplace,” according to Mark J. Rosenfeld, M.S., Ph.D., ANANDA Scientific’s Chief Executive Officer. “ANANDA Scientific, with our partners at the Hebrew University of Jerusalem, LDS Technologies in Israel and others elsewhere, is continuing its progression to bringing effective CBD products to market”.
Poised for Global Growth by New Products and New Partnerships
In February, 2015, ANANDA signed exclusive worldwide licensing and collaboration agreements with Yissum Research Development Company Ltd. (Yissum), the technology transfer company of the Hebrew University of Jerusalem, Israel; Hadasit Ltd. (Hadasit), the technology transfer company of the Hadassah Medical Organization in Jerusalem; and the Kennedy Trust for Rheumatology Research (KIR), Oxford University, United Kingdom. These agreements allow ANANDA Scientific to use its proprietary, non-psychoactive CBD preparations to exclusively treat medical conditions of great public health importance, like diabetes, inflammatory diseases (like arthritis, atherosclerosis and ulcerative colitis) and cardiovascular disorders.
In March 2015, ANANDA Scientific formalized its collaboration with LDS Technologies, an Israeli biotechnology company, to resolve a crucial unmet need for CBD, getting CBD taken by mouth efficiently into the bloodstream and then to sites in the body where it has its effects. This unmet need has now been successfully resolved and the prospect of consistent dosing and predictable therapeutic effects can now become reality for the first time.
The Company will now be entering into refereed human clinical trials with its Israeli partners. These are otherwise lacking for CBD, but essential for achieving regulatory approval and acceptance by healthcare professionals.
About ANANDA Scientific:
ANANDA Scientific, Inc., formerly ISA Scientific, was founded in 2012 with the vision and strategy of making CBD, a non-psychoactive molecule exclusive to cannabis plants, a meaningful human therapeutic. The company has thus focused on the science and technology needed to facilitate and maximize CBD’s tentative benefits. Our research and development have yielded the actionable processes needed to bring meaningful CBD-containing pharmaceutical, nutraceutical and functional food products to market, and with the sincere aim of taking the lead in setting industry standards that otherwise remain lacking. Our founders and advisors include accomplished scientists who have been diligently working on making CBD a worthwhile therapeutics. Some of the most prominent researchers in relevant disciplines have conducted and are working in concert with the ANANDA Scientific. For more information visit http://www.anandascientific.com or contact John Abu-Ulba, COO at (800) 215-3714 or email email@example.com.
For Media Inquiries contact:
Salar Communications Group